Education
About Us
Working with TipRanks
Follow Us
Pharming Group Nv (PHAR)
:PHAR
Earnings Data
Report Date
May 08, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.03Last Year’s EPS
-0.19Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 13, 2025
|% Change Since: 5.30%
|Next Earnings Date:May 08, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth, successful product launches, and strategic acquisitions contributing to a positive outlook for Pharming. However, challenges such as inventory impairment and additional costs from the Abliva acquisition were noted. Despite these challenges, the company's growth prospects and pipeline expansion efforts suggest a positive trajectory.Company Guidance
In the Pharming Group's fourth-quarter and full-year 2024 results conference call, CEO Fabrice Chouraqui highlighted the company's impressive financial performance and strategic vision. The full-year 2024 revenues increased by 21% to $297 million, surpassing guidance, with strong contributions from RUCONEST and Joenja. RUCONEST revenue grew by 11% to $252 million, driven by a 24% increase in new patient enrollments and an 11% expansion in prescriber base. Joenja's revenue soared by 147% to $45 million, supported by the enrollment of new APDS patients and upcoming market launches. The company reported operating profit and positive cash flow in the last two quarters, with guidance for 2025 revenues set between $315 million and $335 million, reflecting a 6% to 13% growth. RUCONEST is expected to maintain its momentum despite new competitors, while Joenja's growth is anticipated to accelerate with new patient enrollments and geographic expansion. The acquisition of Abliva is anticipated to add $30 million in operating expenses for 2025, including $17 million in R&D costs, as Pharming continues to build a diverse portfolio in the rare disease sector.Strong Revenue Growth
Full-year 2024 revenues increased by 21% to $297 million, surpassing guidance. RUCONEST grew 11% to $252 million, and Joenja revenue increased by 147% to $45 million.
Successful Launch and Expansion of Joenja
Joenja was launched in the US and is preparing to launch in other key markets. The drug saw a 147% revenue increase, with 96 patients on paid therapy in the US and additional patients globally.
Acquisition of Abliva
Pharming completed the acquisition of Abliva, which is seen as a stepping stone in the company's development. The acquisition adds a pivotal stage program in mitochondrial disease.
Positive Cash Flow and Operating Profit
Pharming achieved positive operating cash flow and profit in the last two quarters of 2024.
Pipeline Expansion
Pharming expanded its pipeline with promising opportunities, including Phase 2 trials for leniolisib in larger indications like CVID and APLS.
---
PHAR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
PHAR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 13, 2025 | $7.74 | $8.74 | +12.92% |
| Oct 24, 2024 | $8.96 | $8.30 | -7.37% |
| Aug 01, 2024 | $8.33 | $7.63 | -8.40% |
| May 08, 2024 | $9.66 | $9.50 | -1.66% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Pharming Group Nv (PHAR) report earnings?
Pharming Group Nv (PHAR) is schdueled to report earning on May 08, 2025, TBA Not Confirmed.
What is Pharming Group Nv (PHAR) earnings time?
Pharming Group Nv (PHAR) earnings time is at May 08, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PHAR EPS forecast?
PHAR EPS forecast for the fiscal quarter 2025 (Q1) is -0.03.
---